Article
Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists - 1 Mar 2021
Brett Mary Anne, Atenafu Eshetu G, Singh Nilanchali, Ghatage Prafull, Clarke Blaise A, Nelson Gregg S, Bernardini Marcus Q, Köbel Martin
Abstract excerpt
TP53 status is the most important prognostic biomarker in endometrial carcinoma. We asked the question whether p53 mutated endometrial endometrioid carcinomas grade 3 (EEC3) or endometrial serous carcinomas (ESC), the latter ubiquitously harboring TP53 mutation, have different outcomes. TP53 mutation status was assessed by surrogate p53 immunohistochemistry on 326 EEC3 and ESC from 2 major cancer centers in...
Topics
- Aged
- Canada
- Carcinoma, Endometrioid
- Cohort Studies
- Endometrial Neoplasms
- Endometrium
- Female
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Middle Aged
- Mutation
- Prognosis